The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbi, Mali, Makower, Della, Sparano, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366126/
https://www.ncbi.nlm.nih.gov/pubmed/34408795
http://dx.doi.org/10.1177/17588359211038467
Descripción
Sumario:Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays.

Ejemplares similares